Navigation Links
Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria

The research, done in collaboration with the Centro de Investigación Médica Aplicada (CIMA) at the University of Navarra, Pamplona, Spain, is being presented at Porphyrins and Porphyrias Congress, Rotterdam, the Netherlands.

AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam Molecular Therapeutics BV (AMT), a leader in the field of human gene therapy, will today present preclinical data on its AMT-020 gene therapy to treat acute intermittent porphyria (AIP) at the Porphyrins and Porphyrias Congress, Rotterdam.

The data suggest that AMT-020 has the potential to protect patients suffering from recurrent porphyria attacks and/or neuropathy.

AMT-020 is comprised of an Adeno-Associated Virus (AAV) vector delivering the gene for porphobilinogen deaminase (PBGD). The aim of this study, which was performed by Dr's Fontanellas, González-Aseguinolaza and Prieto at CIMA, was to investigate the potential of AMT-020 to protect against acute attack induced by phenobarbital (Pb) in a mouse model of AIP. The model reproduces key features of AIP attack after Pb induction, including increased urinary excretion of haem precursors and decreased motor function.

PBGD-deficient female and male mice were intravenously injected with 1x1011 gc/mouse of AMT-020. Control animals received the same AAV vector but carried the luciferase reporter gene.

One month after injection, both groups were treated with an increasing dose of Pb for 4 days to induce a porphyria attack. The results showed that porphyric mice that received AMT-020 had almost normal haem precursors in the urine and normal motor function, indicating that the treatment completely prevented the occurrence of porphyric attacks.

"These results are very encouraging, and show the potential of AMT-020 to treat AIP," said Sander van Deventer, CSO at AMT, who presented the data. "The next stage in the development of the
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
10. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
11. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB:MIV), a leading ... delivery systems for,cardiovascular stents and other implantable ... sponsored bench test confirmed that,merging Biosync Scientific's ... acquired, with the Company's polymer-free drug,delivery system ...
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
Cached Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... AZ (PRWEB) August 30, 2014 Hastings ... personal injury attorneys located throughout Arizona is pleased to ... This is one specific example among many cases where ... clients are able to retain a greater portion of ... after case that providing a positive solution for Arizona ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web ... is now offering discount for Labor Day on ... on putting forward the best of web development technology ... team of professionals and web developers and designers has ... the critical issues of web development and can develop ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... 12 Blue Cross of California,highly values the trust ... with their physicians and medical groups. It is,our responsibility ... to date,both for the benefit of our members and ... we do this is to send the member,s application ...
... ... New Event Name ... Same Commitment to ... the Health of all Babies, ... pleased to announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family ... Formerly known as WalkAmerica,March for Babies is the March of Dimes premier ...
... Feb. 12 Echo Therapeutics,Inc. (OTC Bulletin Board: ... that it had completed an approximately,$2.3 million private ... VII, LLC and certain other select institutional and ... The $2,292,459 in aggregate principal amount of ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
... DARIEN, Ill., Feb. 12 Darien, IL-based Healthation,announced ... Provider Portal to deliver interactive self-service,capabilities to its ... track record of integrating with the plan,s existing ... claims directly through the,provider portal., The AboveHealth ...
... MENLO PARK, Calif., Feb. 12 XTENT, Inc.,(Nasdaq: ... results for 2007,after market close on Tuesday, February 19, ... day at 2 p.m., Pacific Time (5 p.m. Eastern ... XTENT,s President and Chief,Executive Officer, and Tim Kahlenberg, Chief ...
Cached Medicine News:Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2Health News:PrimeWest Health Chooses Healthation's AboveHealth as Next Generation Provider Portal 2
An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
Compressor-cooled plate used to keep blocks cold while sectioning....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus EGL Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2, electrolytes, glucose and lactate (lactic acid)....
Medicine Products: